Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at $3,738,560. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 142.41 on Friday. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $145.41. The company has a market cap of $31.78 billion, a P/E ratio of 61.76 and a beta of 1.41. The company’s 50 day moving average is $134.32 and its 200 day moving average is $123.75.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company had revenue of $912 million during the quarter, compared to analysts’ expectations of $846.15 million. During the same quarter in the prior year, the company posted $1.13 earnings per share. Alexion Pharmaceuticals’s revenue for the quarter was up 21.1% compared to the same quarter last year. On average, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/julie-oneill-sells-11160-shares-of-alexion-pharmaceuticals-inc-alxn-stock/1535365.html.

A number of large investors have recently bought and sold shares of ALXN. Guardian Life Insurance Co. of America boosted its stake in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Eqis Capital Management Inc. boosted its stake in Alexion Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 38 shares during the last quarter. Rathbone Brothers plc boosted its stake in Alexion Pharmaceuticals by 2.5% in the second quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 50 shares during the last quarter. Cleararc Capital Inc. boosted its stake in Alexion Pharmaceuticals by 1.0% in the first quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 53 shares during the last quarter. Finally, Seven Bridges Advisors LLC boosted its stake in Alexion Pharmaceuticals by 2.1% in the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 53 shares during the last quarter. 94.26% of the stock is owned by institutional investors.

Several research firms have issued reports on ALXN. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 20th. Evercore ISI began coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, August 16th. They set an “in-line” rating and a $137.00 target price for the company. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price for the company in a report on Wednesday, August 2nd. BMO Capital Markets reiterated an “outperform” rating and set a $168.00 target price (up from $159.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. Finally, Leerink Swann increased their target price on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the stock an “outperform” rating in a report on Friday, July 28th. Six research analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $156.13.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.